Boothbay Fund Management, LLC Cogent Biosciences, Inc. Transaction History

Boothbay Fund Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$9.39 - $16.99 $129,093 - $233,578	-13,748 Reduced 41.04%	19,752 $295,000
Q2 2022 Aug 15, 2022	BUY	$3.92 - $9.73 $131,320 - $325,955	33,500 New	33,500 $302,000
Q2 2021 Aug 16, 2021	SELL	$7.82 - $9.3 $86,872 - $103,313	-11,109 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$7.47 - $12.34 $82,984 - $137,085	11,109 New	11,109 $98,000

173

114M

56.7K

40.4K

Ticker COGT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,758,300
Market Cap $549M
Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.